Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA:688443)
26.84
+1.22 (4.76%)
At close: Mar 6, 2026
SHA:688443 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | - | 2,035 | 2,892 | 49.28 | 14.15 |
Trading Asset Securities | - | 412.58 | 27.71 | 237.36 | 427.11 |
Cash & Short-Term Investments | 2,316 | 2,448 | 2,920 | 286.64 | 441.25 |
Cash Growth | -5.39% | -16.16% | 918.65% | -35.04% | 684.19% |
Accounts Receivable | - | 12.01 | - | - | - |
Other Receivables | - | 1.38 | 0 | - | 1.53 |
Receivables | - | 13.38 | 0 | - | 1.53 |
Inventory | - | 50.15 | 55.45 | 56.33 | 33.66 |
Other Current Assets | - | 110.59 | 56.56 | 56.03 | 52.76 |
Total Current Assets | - | 2,622 | 3,032 | 399 | 529.2 |
Property, Plant & Equipment | - | 441.55 | 487.82 | 487.75 | 327.83 |
Other Intangible Assets | - | 43.59 | 43.54 | 45.08 | 45.92 |
Long-Term Deferred Charges | - | 25.16 | 27.92 | 25.51 | 23.51 |
Other Long-Term Assets | - | 13.26 | 3.46 | 4.77 | 76.36 |
Total Assets | - | 3,146 | 3,595 | 962.11 | 1,003 |
Accounts Payable | - | 67.06 | 83.04 | 67.84 | 46.61 |
Accrued Expenses | - | 63.03 | 37.74 | 29.71 | 24.29 |
Short-Term Debt | - | - | 0.63 | - | - |
Current Portion of Long-Term Debt | - | 26.24 | - | 5.3 | 0.9 |
Current Portion of Leases | - | 12.13 | 10.07 | 7.64 | 6.51 |
Other Current Liabilities | - | 5.82 | 5.4 | 15.87 | 7.7 |
Total Current Liabilities | - | 174.29 | 136.87 | 126.37 | 86.01 |
Long-Term Debt | - | 786.13 | 608.48 | 738.59 | 535.55 |
Long-Term Leases | - | 12.63 | 21.82 | 30.37 | 28.65 |
Long-Term Unearned Revenue | - | 46.62 | 43.2 | 37.69 | 35.55 |
Other Long-Term Liabilities | - | - | - | - | 5.08 |
Total Liabilities | - | 1,020 | 810.36 | 933.03 | 690.84 |
Common Stock | - | 366.68 | 366.68 | 275 | 275 |
Additional Paid-In Capital | - | 4,192 | 4,038 | 573.29 | 279.82 |
Retained Earnings | - | -2,418 | -1,621 | -819.21 | -242.84 |
Treasury Stock | - | -14.67 | - | - | - |
Shareholders' Equity | 1,788 | 2,126 | 2,784 | 29.08 | 311.98 |
Total Liabilities & Equity | - | 3,146 | 3,595 | 962.11 | 1,003 |
Total Debt | 1,047 | 837.13 | 640.99 | 781.91 | 571.6 |
Net Cash (Debt) | 1,269 | 1,611 | 2,279 | -495.27 | -130.35 |
Net Cash Growth | -21.23% | -29.31% | - | - | - |
Net Cash Per Share | 3.48 | 4.38 | 7.11 | -1.80 | -0.47 |
Filing Date Shares Outstanding | 362.65 | 366.68 | 366.68 | 275 | 275 |
Total Common Shares Outstanding | 366.68 | 366.68 | 366.68 | 275 | 275 |
Working Capital | - | 2,448 | 2,895 | 272.63 | 443.19 |
Book Value Per Share | 4.88 | 5.80 | 7.59 | 0.11 | 1.13 |
Tangible Book Value | 1,745 | 2,082 | 2,741 | -15.99 | 266.06 |
Tangible Book Value Per Share | 4.76 | 5.68 | 7.47 | -0.06 | 0.97 |
Buildings | - | 115.03 | 114.98 | 105.89 | 99.77 |
Machinery | - | 516.53 | 457.63 | 302.65 | 261.93 |
Construction In Progress | - | 6.74 | 52.18 | 164.82 | 18.27 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.